Wikidata entity: Q425729
C₂₇H₃₆N₂O₅ (P274)
Contact
| P856 | official website | https://www.corlanorhcp.com |
Quantities
| P4250 | defined daily dose | 10 |
| P2067 | mass | 468.262422 |
| P3780 | active ingredient in | ... | Q47521405 (Corlanor) | Corlanor |
| P233 | canonical SMILES | String | CN(CCCN1CCC2=CC(=C(C=C2CC1=O)OC)OC)CC3CC4=CC(=C(C=C34)OC)OC | ??? |
| P373 | Commons category | String | Ivabradine | ??? |
| P366 | has use | ... | Q12140 (medication) | medication |
| P31 | instance of | ... | Q113145171 (type of chemical entity) | type of chemical entity |
| P2017 | isomeric SMILES | String | CN(CCCN1CCC2=CC(=C(C=C2CC1=O)OC)OC)C[C@H]3CC4=CC(=C(C=C34)OC)OC | ??? |
| P8026 | LiverTox likelihood score | ... | Q83284667 (LiverTox toxicity likelihood category E) | LiverTox toxicity likelihood category E |
| P2175 | medical condition treated | ... | Q847583 (cardiomyopathy) | cardiomyopathy |
| P2175 | medical condition treated | ... | Q19000661 (congestive heart failure) | congestive heart failure |
| P129 | physically interacts with | ... | Q21115989 (Hyperpolarization activated cyclic nucleotide gated potassium channel 1) | Hyperpolarization activated cyclic nucleotide gated potassium channel 1 |
| P129 | physically interacts with | ... | Q21115996 (Hyperpolarization activated cyclic nucleotide gated potassium channel 3) | Hyperpolarization activated cyclic nucleotide gated potassium channel 3 |
| P129 | physically interacts with | ... | Q21115998 (Hyperpolarization activated cyclic nucleotide gated potassium channel 4) | Hyperpolarization activated cyclic nucleotide gated potassium channel 4 |
| P129 | physically interacts with | ... | Q21982207 (Hyperpolarization-activated, cyclic nucleotide-gated K+ 2) | Hyperpolarization-activated, cyclic nucleotide-gated K+ 2 |
| P129 | physically interacts with | ... | Q21982210 (Hyperpolarization activated cyclic nucleotide gated potassium channel 1) | Hyperpolarization activated cyclic nucleotide gated potassium channel 1 |
| P3489 | pregnancy category | ... | Q3679274 (Australian pregnancy category D) | Australian pregnancy category D |
| P636 | route of administration | ... | Q285166 (oral administration) | oral administration |
| P769 | significant drug interaction | ... | Q7739 (arsenic trioxide) | arsenic trioxide |
| P769 | significant drug interaction | ... | Q118551 (clarithromycin) | clarithromycin |
| P769 | significant drug interaction | ... | Q144085 (pimozide) | pimozide |
| P769 | significant drug interaction | ... | Q174259 (droperidol) | droperidol |
| P769 | significant drug interaction | ... | Q179996 ((RS)-methadone) | (RS)-methadone |
| P769 | significant drug interaction | ... | Q213511 (erythromycin) | erythromycin |
| P769 | significant drug interaction | ... | Q228143 (zuclopenthixol) | zuclopenthixol |
| P769 | significant drug interaction | ... | Q251347 (haloperidol) | haloperidol |
| P769 | significant drug interaction | ... | Q407883 (ketoconazole) | ketoconazole |
| P769 | significant drug interaction | ... | Q407972 (chlorpromazine) | chlorpromazine |
| P769 | significant drug interaction | ... | Q408637 (dronedarone) | dronedarone |
| P769 | significant drug interaction | ... | Q409672 ((RS)-citalopram) | (RS)-citalopram |
| P769 | significant drug interaction | ... | Q410061 (amiodarone) | amiodarone |
| P769 | significant drug interaction | ... | Q410291 (verapamil) | verapamil |
| P769 | significant drug interaction | ... | Q411229 (itraconazole) | itraconazole |
| P769 | significant drug interaction | ... | Q412236 (voriconazole) | voriconazole |
| P769 | significant drug interaction | ... | Q421937 ((RS)-hydroxyzine) | (RS)-hydroxyzine |
| P769 | significant drug interaction | ... | Q422229 (diltiazem) | diltiazem |
| P769 | significant drug interaction | ... | Q412690 (galantamine) | galantamine |
| P769 | significant drug interaction | ... | Q413591 (sotalol) | sotalol |
| P769 | significant drug interaction | ... | Q415081 (donepezil) | donepezil |
| P769 | significant drug interaction | ... | Q422418 ((RS)-sulpiride) | (RS)-sulpiride |
| P769 | significant drug interaction | ... | Q422618 (ritonavir) | ritonavir |
| P769 | significant drug interaction | ... | Q424940 (moxifloxacin) | moxifloxacin |
| P769 | significant drug interaction | ... | Q425120 (disopyramide) | disopyramide |
| P769 | significant drug interaction | ... | Q425137 (fingolimod) | fingolimod |
| P769 | significant drug interaction | ... | Q906453 (posaconazole) | posaconazole |
| P769 | significant drug interaction | ... | Q3896970 (pasireotide) | pasireotide |
| P769 | significant drug interaction | ... | Q3993743 ((Z)-Toremifene) | (Z)-Toremifene |
| P769 | significant drug interaction | ... | Q5186964 (crizotinib) | crizotinib |
| P769 | significant drug interaction | ... | Q5473363 (fosphenytoin) | fosphenytoin |
| P769 | significant drug interaction | ... | Q7914515 (vandetanib) | vandetanib |
| P3364 | stereoisomer of | ... | Q27273145 ((-)-ivabradine) | (-)-ivabradine |
| P279 | subclass of | ... | Q27275319 ((+/-)-ivabradine) | (+/-)-ivabradine |
| P2868 | subject has role | ... | Q50429907 (cardiovascular agent) | cardiovascular agent |
Why not click here or view trends?
log id: None